Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
MS Sulkowski, DF Gardiner… - … England Journal of …, 2014 - Mass Medical Soc
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
[PDF][PDF] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
MS Sulkowski, DF Gardiner, M Rodriguez-Torres… - N Engl J Med, 2014 - natap.org
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
[引用][C] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
MS Sulkowski, DF Gardiner… - New England Journal …, 2014 - cir.nii.ac.jp
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
MS Sulkowski, DF Gardiner… - The New England …, 2014 - europepmc.org
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
MS Sulkowski, DF Gardiner… - … England Journal of …, 2014 - pure.johnshopkins.edu
Background: All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
[引用][C] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
MS SULKOWSKI, DF GARDINER… - The New England …, 2014 - pascal-francis.inist.fr
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[PDF][PDF] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
MS Sulkowski, DF Gardiner… - N Engl J …, 2014 - gruposdetrabajo.sefh.es
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
[PDF][PDF] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
MS Sulkowski, DF Gardiner, M Rodriguez-Torres… - N Engl J Med, 2014 - academia.edu
Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
MS Sulkowski, DF Gardiner, M Rodriguez-Torres… - 2014 - cabidigitallibrary.org
BACKGROUND: All-oral combination therapy is desirable for patients with chronic hepatitis
C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex …
C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex …
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
MS Sulkowski, DF Gardiner… - … England Journal of …, 2014 - scholars.uthscsa.edu
Background: All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …